ArticleGlobal health & medicine2021
Elevated high-sensitivity troponin is associated with subclinical cardiac dysfunction in patients recovered from coronavirus disease 2019.
Article in Global health & medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- ESCMID rapid guidelines for assessment and management of long COVID.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Guideline
- Myocardial Work Indices in Patients Recently Recovered from Mild-to-Moderate COVID-19.Journal of clinical medicine · 2024Article
- Hypertension as One of the Main Non-Myocardial Infarction-Related Causes of Increased Cardiospecific Troponins: From Mechanisms to Significance in Current Medical Practice.Journal of clinical medicine research · 2022Review
- Cardiac Troponins as Biomarkers of Cardiac Myocytes Damage in Case of Arterial Hypertension: From Pathological Mechanisms to Predictive Significance.Life (Basel, Switzerland) · 2022Review
- Preliminary Guidelines for the Clinical Evaluation and Management of Long COVID.Infection & chemotherapy · 2022Review
- Cardiovascular considerations during the COVID-19 pandemic: A focused review for practice in Japan.Global health & medicine · 2022Review
- Role of Cardiac Imaging Modalities in the Evaluation of COVID-19-Related Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2022Review
- Cardiovascular implications of the COVID-19 pandemic.Journal of cardiology · 2022Review
- Interleukin-6 is upregulated and may be associated with myocardial injury in some patients who have recovered from COVID-19.Global health & medicine · 2022Article
- Association between global longitudinal strain and clinical outcomes following COVID-19 infection.Clinical cardiology · 2022Article
- Mild COVID-19 induces early, quantifiable, persistent troponin I elevations in elder men.Frontiers in cardiovascular medicine · 2022Article
- SARS-CoV-2 surreptitiously injures the heart of Japanese: echocardiography is useful in evaluating cardiac damage.Global health & medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study is to investigate myocardial damage in recovering coronavirus disease 2019 (COVID-19) patients with high-sensitivity troponin levels (hsTnT) and echocardiography. In this single-center cohort study, 215 COVID-19 recovered patients were recruited from all over Japan between April and September 2020. Demographic characteristics, hsTnT levels, and echocardiography data were collected for 209 patients, after excluding those without serum samples or good-quality echocardiographic images. The mean (± standard deviation) age was 44 (± 12) years (range: 36-55 years), and 50.7% of the patients were males. The median time interval (interquartile range) from COVID-19 onset to post-recovery examination was 56 days (34-96 days). Seventy-four recovered patients (35.4%) had hsTnT less than detection sensitivity (< 3 pg/mL) and 135 recovered patients (64.6%) had hsTnT ≥ 3 pg/mL. Ejection fraction was more than 50% in all cases. Left ventricular global longitudinal strain (LVGLS) and right ventricular free-wall longitudinal strain (RVFWLS) were reduced in 62 (29.7%) and 8 patients (3.8%), respectively. They were significantly associated with elevated hsTnT levels. In cases with hsTnT above 5 pg/mL, the LVGLS was greatly reduced to 19.0 ± 2.2% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.